Yandex Metrika
0

Endometriosis niclosamide nanodendrimers treatment is transforming gynecological care into a targeted, non-hormonal nanomedicine revolution: researchers have achieved a breakthrough by engineering a nanoscale drug delivery platform for the FDA-approved anthelmintic agent niclosamide. In a landmark study published in Advanced Healthcare Materials, a collaborative team led by Dr. Sharma and Prof. Hayashi demonstrated that conjugating niclosamide to polyamidoamine (PAMAM) nanodendrimers selectively accumulates within ectopic endometriotic lesions, systematically shuts down aberrant Wnt/β-catenin and STAT3 signaling, and induces up to an 85% regression of lesions without compromising ovarian function or hormonal balance.

The Silent Epidemic: The Dead End of Hormonal Suppression in Endometriosis

Endometriosis is an aggressive, chronic inflammatory condition affecting more than 190 million women of reproductive age worldwide — roughly one in every ten women. The disease is defined by the extrauterine implantation and proliferation of functional endometrial-like stromal and epithelial tissue across the pelvic peritoneum, ovaries, fallopian tubes, bowel, and bladder. During each menstrual cycle, these ectopic implants undergo shedding and micro-hemorrhage, driving widespread peritoneal fibrosis, dense adhesions, debilitating pelvic pain, and infertility.

Conventional therapeutic regimens have long remained palliative and systemic. First-line therapies rely on gonadotropin-releasing hormone (GnRH) agonists, oral progestins, or combined contraceptives to induce pharmacological hypogonadism — effectively plunging young women into premature menopause. The associated adverse events include accelerated bone mineral loss, vasomotor hot flashes, severe affective disorders, and complete contraception during active treatment.

Laparoscopic surgical ablation exhibits high recurrence rates exceeding 50% within five years, with repeat surgical procedures progressively degrading ovarian reserve. The clinical community urgently needed a targeted, non-hormonal antiproliferative modality capable of directly ablating ectopic stromal lesions.

Лабораторные флаконы и пипетки с наносомальными биомедицинскими препаратами
Synthesis of polyamidoamine dendrimers and targeted release of niclosamide in endometriotic lesions. Photo: Vinegret

The Rebirth of Niclosamide: Unlocking a Potent Multipathway Inhibitor

Niclosamide was originally approved by the FDA more than six decades ago as an oral antihelminthic medication for intestinal tapeworm infestations. However, modern high-throughput phenotypic screening campaigns uncovered that niclosamide possesses a potent pleiotropic pharmacological profile against hyperproliferative disorders.

Biochemical analyses revealed that niclosamide functions as a mitochondrial uncoupling agent while serving as a potent inhibitor of multiple oncogenic signaling pathways, including Wnt/beta-catenin, STAT3, NF-kappaB, and mTOR cascades. Crucially, these precise cascades are hyperactivated in endometriotic stromal cells, providing them with pathological resistance to apoptosis, invasive motility, and the ability to trigger extensive neo-angiogenesis.

Yet direct translation of niclosamide remained obstructed by poor biophysical properties: extreme lipophilicity and near-zero aqueous solubility. Oral administration results in minimal systemic bioavailability, with over 90% eliminated through the gastrointestinal tract without reaching therapeutic thresholds in the pelvic cavity.

Targeted PAMAM Nanodendrimers

Hyperbranched 4-nanometer polymeric carriers navigate biological barriers, delivering high drug payloads directly to lesions.

Niclosamide Repurposing

The antihelminthic compound dismantles Wnt/β-catenin and STAT3 cascades, reducing endometriotic lesion volume by 85%.

Non-Hormonal Safety Profile

Therapy preserves natural estradiol cycles, protects ovarian follicle reserve, and maintains reproductive capability.

Fibrosis & Adhesion Prevention

Halting local VEGF and interleukin synthesis eliminates pelvic collagen scarring and resolves chronic debilitating pain.

The Nanodendrimer Scaffold: Overcoming Solubility and Biological Barriers

To overcome this pharmacological bottleneck, the research group synthesized fourth-generation polyamidoamine dendrimers (G4 PAMAM Dendrimers). Dendrimers are radially symmetric, monodisperse polymeric macromolecules measuring 4 to 5 nanometers in hydrodynamic diameter with dense surface functionality.

The hydrophobic interior cavities of the PAMAM architecture encapsulate niclosamide molecules at high loading capacity, while the external periphery is PEGylated and conjugated with targeting peptide ligands designed to bind alpha-v-beta-3 integrins overexpressed on endometriotic vascular endothelial cells.

Exploiting the enhanced permeability and retention (EPR) effect, these targeted nanodendrimers selectively extravasate through leaky neovascular endothelium into endometriotic implants, while completely avoiding normal myometrium and ovarian follicles. In a manner parallel to how advanced photochromic biotechnology formulations functionalize organic surfaces, targeted dendrimers establish a localized drug reservoir directly within diseased tissue.

«Endometriosis management has remained trapped in a pharmaceutical dead-end for decades: patients were offered either aggressive surgical excision of adhesions or chemical menopause with severe bone-mineral and psychological sequelae. Our dendrimer-based niclosamide nanoplatform attacks the molecular roots of inflammation and neo-angiogenesis while preserving ovarian reserve and fertility intact.»

Dr. Ritu Sharma and Prof. Kazuhiro Hayashi, principal authors, published in Advanced Healthcare Materials

Molecular Cascades: Suppressing Angiogenesis, Fibrosis, and Inflammation

Following endocytosis into pathological endometriotic stromal cells, the acid-labile linkers trigger controlled intracellular release of niclosamide within acidic endo-lysosomal compartments, initiating targeted programmed cell death.

Preclinical in vivo studies demonstrated that dendrimer-formulated niclosamide induced rapid mitochondrial membrane depolarization, blocked STAT3 phosphorylation, and facilitated ubiquitin-dependent proteasomal degradation of beta-catenin. Consequently, local secretion of vascular endothelial growth factor (VEGF) plummeted by 78%, starving the ectopic implants of blood supply.

Simultaneously, the formulation inhibited the release of key proinflammatory cytokines, specifically IL-6, IL-8, and TNF-alpha, while preventing fibroblast-to-myofibroblast transdifferentiation. This halted type I collagen deposition, preventing the formation of rigid pelvic adhesions that cause excruciating pain.

Key Innovations of Niclosamide Nanotherapy for Endometriosis:
  • Overcomes niclosamide aqueous insolubility via encapsulation in generation-4 PAMAM dendrimers.
  • Achieves targeted accumulation in pelvic lesions utilizing alpha-v-beta-3 integrin ligands and vascular EPR effect.
  • Inhibits Wnt/beta-catenin and STAT3 cascades, driving apoptotic regression of ectopic stromal cells.
  • Completely avoids hormonal menopause side effects, protecting ovarian reserve and fertility.

Translational Horizon: Preserving Ovarian Reserve and Advancing Trials

The defining clinical breakthrough of this nanodendrimer delivery paradigm is its preservation of endocrine homeostasis. Unlike conventional GnRH therapies, niclosamide nanotherapy does not perturb serum concentrations of estradiol, progesterone, or luteinizing hormone. Treated cohorts sustained normal estrous cycles and achieved uncompromised pregnancy rates and healthy litters immediately following treatment.

Comprehensive systemic toxicology evaluations verified zero organ accumulation or histopathological damage across hepatic and renal tissues, as the PEGylated nanodendrimers undergo renal clearance within 48 hours.

The research team is actively progressing toward Phase I human clinical trials. Complete synthetic protocols and molecular biodistribution maps are accessible in Advanced Healthcare Materials.

Video: Nanotechnology in medicine and targeted drug delivery systems in pathological tissues (Nanotechnology in Medicine)
Found a typo or error? Highlight it and press Ctrl + Enter

Follow our latest updates:


Like it? Share with your friends!

✏️ Report a typo or mistake

You noticed a mistake in the following text: